Saniona (DB:30S) - Cotización, noticias y análisis

Resumen de acción 30S

Saniona AB (publ), empresa biofarmacéutica, se dedica a la investigación, desarrollo y comercialización de tratamientos para pacientes con enfermedades raras en Dinamarca.

Acerca de la empresa

30S fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	2/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Recompensas

Se prevé un crecimiento anual de los ingresos de 43.56%

Análisis de riesgos

Tiene menos de 1 año de cash runway

Los accionistas han sido diluidos sustancialmente en el último año

Patrimonio neto negativo

Actualmente no es rentable y no se prevé que lo sea en los próximos 3 años

+ 3 riesgos adicionales

Competidores de Saniona AB (publ)

co.don

XTRA:CNW

€6.5m

Medigene

XTRA:MDG1

€37.0m

Paion

XTRA:PA8

€2.6m

2invest

XTRA:2INV

€50.6m

Historial de precios y rendimiento

Summary of all time highs, changes and price drops for Saniona
Historical stock prices
Current Share Price	kr0.13
52 Week High	kr0.96
52 Week Low	kr0.12
Beta	1
1 Month Change	-4.61%
3 Month Change	-20.43%
1 Year Change	-78.22%
3 Year Change	-94.04%
5 Year Change	-94.37%
Change since IPO	-95.47%

Noticias y actualizaciones recientes

Recent updates

Rentabilidad de los accionistas

	30S	DE Biotechs	Mercado DE
7D	0.9%	0.7%	2.0%
1Y	-78.2%	-24.4%	2.0%

Rentabilidad vs. Industria: 30S obtuvo unos resultados inferiores a los del sector German Biotechs , que el año pasado arrojó un rendimiento del -23%.

Rentabilidad vs. Mercado: 30S obtuvo unos resultados inferiores a los del mercado German, que fue del 2.3% el año pasado.

Volatilidad de los precios

Is 30S's price volatile compared to industry and market?
30S volatility
30S Average Weekly Movement	9.8%
Biotechs Industry Average Movement	5.0%
Market Average Movement	4.9%
10% most volatile stocks in DE Market	10.2%
10% least volatile stocks in DE Market	2.5%

Precio estable de las acciones: El precio de las acciones de 30S ha sido volátil en los últimos 3 meses.

Volatilidad a lo largo del tiempo: La volatilidad semanal de 30S(10%) se ha mantenido estable durante el último año, pero sigue siendo superior al 75% de las acciones de German.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
2011	23	Thomas Feldthus	www.saniona.com

Saniona AB (publ), empresa biofarmacéutica, se dedica a la investigación, desarrollo y comercialización de tratamientos para pacientes con enfermedades raras en Dinamarca. También desarrolla medicamentos que modulan los canales iónicos. Entre los productos de la empresa figuran la tesofensina, un inhibidor de la recaptación de monoaminas, y el tesomet, una combinación de dosis fija de tesofensina y metoprolol que ha completado los ensayos clínicos de fase 2 para el tratamiento del síndrome de Prader-Willi y la obesidad hipotalámica.

Resumen de fundamentos de Saniona AB (publ)

¿Cómo se comparan los beneficios e ingresos de Saniona con su capitalización de mercado?
Estadísticas fundamentales de 30S
Capitalización bursátil	€17.67m
Beneficios(TTM)	-€8.19m
Ingresos (TTM)	€1.44m

12.3x

Ratio precio-ventas (PS)

-2.2x

Ratio precio-beneficio (PE)

¿Está 30S sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de 30S
Ingresos	kr16.84m
Coste de los ingresos	kr5.06m
Beneficio bruto	kr11.78m
Otros gastos	kr107.59m
Beneficios	-kr95.81m

Últimos beneficios comunicados

Dec 31, 2023

Próxima fecha de beneficios

Apr 30, 2024

Beneficios por acción (BPA)	-0.86
Margen bruto	69.96%
Margen de beneficio neto	-568.94%
Ratio deuda/patrimonio	-297.3%

¿Cómo se ha desempeñado 30S a largo plazo?

Ver rendimiento histórico y comparativa

Resumen de acción 30S

Recompensas

Análisis de riesgos

Competidores de Saniona AB (publ)

XTRA:CNW

€6.5m

XTRA:MDG1

€37.0m

XTRA:PA8

€2.6m

XTRA:2INV

€50.6m

Historial de precios y rendimiento

Noticias y actualizaciones recientes

Saniona AB (publ) to Report Fiscal Year 2023 Results on Apr 30, 2024

New major risk - Negative shareholders equity

Full year 2023 earnings released: kr1.49 loss per share (vs kr3.93 loss in FY 2022)

Saniona Announces the Selection of Its Proprietary GABAA A5 Negative Allosteric Modulator (NAM) Lead Compound, San2465

Saniona AB (publ) Strengthens Epilepsy Pipeline with Selection of SAN2355 as Clinical Candidate

Third quarter 2023 earnings released: kr0.38 loss per share (vs kr0.28 profit in 3Q 2022)

Recent updates

Saniona AB (publ) to Report Fiscal Year 2023 Results on Apr 30, 2024

New major risk - Negative shareholders equity

Full year 2023 earnings released: kr1.49 loss per share (vs kr3.93 loss in FY 2022)

Saniona Announces the Selection of Its Proprietary GABAA A5 Negative Allosteric Modulator (NAM) Lead Compound, San2465

Saniona AB (publ) Strengthens Epilepsy Pipeline with Selection of SAN2355 as Clinical Candidate

Third quarter 2023 earnings released: kr0.38 loss per share (vs kr0.28 profit in 3Q 2022)

Saniona AB (publ) to Report Fiscal Year 2024 Results on Feb 27, 2025

Saniona AB (publ), Annual General Meeting, May 29, 2024

Saniona Promotes Kv7 Epilepsy Compound to Candidate Selection Phase

New major risk - Revenue and earnings growth

Second quarter 2023 earnings released: kr0.34 loss per share (vs kr1.42 loss in 2Q 2022)

New minor risk - Shareholder dilution

First quarter 2023 earnings released: kr0.35 loss per share (vs kr2.14 loss in 1Q 2022)

Full year 2022 earnings released: kr3.93 loss per share (vs kr6.59 loss in FY 2021)

Saniona AB Appoints Nomination Committee for the Annual General Meeting 2023

Third quarter 2022 earnings released: EPS: kr0.28 (vs kr1.50 loss in 3Q 2021)

Saniona AB (publ) to Report Q1, 2023 Results on May 25, 2023

Insufficient new directors

Saniona AB (publ) Announces Anti-Inflammatory and Anti-Fibrotic Candidate SAN903 Is Ready for Clinical Studies

Second quarter 2022 earnings released: kr1.42 loss per share (vs kr1.67 loss in 2Q 2021)

Saniona Progresses Its Kv7 Epilepsy Program into Lead Optimization

Saniona Reports Positive Top Line Results from the SAN711 Phase 1 Clinical Trial

Insufficient new directors

Saniona’S Preclinical Candidate San903 Shows Robust Dampening of Fibrosis in Chronic Kidney Disease Model

Saniona Provides Update on Ongoing Review of Tesofensine in Mexico

Saniona Appoints Anita Milland as Chief Financial Officer, Effective April 30, 2022

Saniona Announces Voluntary Pause of Phase 2B Clinical Trials of Tesomet for Hypothalamic Obesity and Prader-Willi Syndrome

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Saniona AB (publ) to Report Fiscal Year 2021 Final Results on Apr 29, 2022

Saniona Initiates Multiple Ascending Dose Stage of SAN711 Phase 1 Clinical Trial

Saniona Initiates Phase 2b Clinical Trial of Tesomet for Prader-Willi Syndrome

Third quarter 2021 earnings released: kr1.50 loss per share (vs kr1.24 loss in 3Q 2020)

Second quarter 2021 earnings released: kr1.67 loss per share (vs kr1.24 loss in 2Q 2020)

Saniona Initiates Phase 1 Clinical Trial of SAN711

Saniona to Present Preclinical Data on SAN711 at the 7th Congress of the European Academy of Neurology

First quarter 2021 earnings released: kr1.34 loss per share (vs kr1.47 profit in 1Q 2020)

Full year 2020 earnings released: kr1.79 loss per share (vs kr2.95 loss in FY 2019)

Saniona Receives Feedback from U.S. FDA Providing a Regulatory Path Forward for Tesomet in Hypothalamic Obesity

Saniona Receives U.S. FDA Orphan Drug Designation for Tesomet in Prader-Willi Syndrome

New 90-day low: €1.81

Novartis AG (SWX:NOVN) completed the acquisition of Cadent Therapeutics, Inc. from a group of sellers.

New 90-day low: €1.97

Saniona Announces Management Appointments

Co-Founder recently bought €11k worth of stock

New 90-day low: €2.07

Third quarter 2020 earnings released: kr1.24 loss per share

Third quarter 2020 earnings released: kr1.24 loss per share

Saniona AB (publ) to Report Fiscal Year 2021 Results on Feb 24, 2022

Saniona AB (publ) Appoints Nomination Committee Members

Saniona Reports Positive Topline Results from Tesomet Phase 2 Open-Label Extension Study in Hypothalamic Obesity

New 90-day low: €2.37

Saniona Receives Pre-IND Feedback from FDA on Regulatory Path for Tesomet in Prader-Willi Syndrome (PWS) and Hypothalamic Obesity (HO)

Earnings released

Saniona AB (publ) has completed a Follow-on Equity Offering in the amount of $64.999993 million.

New 90-day high - €3.69

An unknown buyer acquired 3.96% stake in Scandion Oncology A/S (NGM:SCOL) from Saniona AB (publ) (OM:SANION) for for $2.3 million.

New 90-day high - €2.83

Rentabilidad de los accionistas

Volatilidad de los precios